| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389506A1 Nucleic acid-containing complex |
| 05/17/2001 | CA2389386A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 05/17/2001 | CA2389330A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2389176A1 A method and composition for treating prostate cancer |
| 05/17/2001 | CA2388918A1 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 05/17/2001 | CA2388914A1 15 human secreted proteins |
| 05/17/2001 | CA2388912A1 6 human secreted proteins |
| 05/17/2001 | CA2388643A1 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | CA2388343A1 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387964A1 22 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | CA2386876A1 Combination chemotherapy |
| 05/16/2001 | EP1099706A2 Estrane sulphamate derivatives as steroid sulphatase inhibitors |
| 05/16/2001 | EP1099693A1 Radiolabelled peptide compounds |
| 05/16/2001 | EP1099443A1 Transplant/implant device and method for its production |
| 05/16/2001 | EP1098986A2 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe) |
| 05/16/2001 | EP1098985A1 Genes of the dead box protein family, their expression products and use |
| 05/16/2001 | EP1098981A1 A mutant human hepatitis b viral strain and uses thereof |
| 05/16/2001 | EP1098979A2 Fap alpha-specific antibody with improved producibility |
| 05/16/2001 | EP1098978A1 Gbs toxin receptor |
| 05/16/2001 | EP1098974A2 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| 05/16/2001 | EP1098962A2 Diacylglycerol acyl transferase proteins |
| 05/16/2001 | EP1098960A2 Agents for the immunotherapy of tumoral diseases |
| 05/16/2001 | EP1098909A1 Hybrid human/rodent igg antibody to cd3, and methods of its construction |
| 05/16/2001 | EP1098892A1 Biphenyl derivatives |
| 05/16/2001 | EP1098885A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 05/16/2001 | EP1098666A2 Water-soluble drugs and methods for their production |
| 05/16/2001 | EP1098665A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 05/16/2001 | EP1098663A1 Slow release formulations comprising anionic polysaccharide |
| 05/16/2001 | EP1098656A2 Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof |
| 05/16/2001 | EP1098654A1 Antilipemic composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP1098651A2 Novel urokinase inhibitors |
| 05/16/2001 | EP1098643A2 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| 05/16/2001 | EP1098640A1 Anti-ulcer composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP1098636A1 A wet granulation method for preparing a stable pharmaceutical formulation |
| 05/16/2001 | EP1098631A1 Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy |
| 05/16/2001 | EP0994948B1 Tgf beta rii receptor nucleic sequence, coded peptide, and uses |
| 05/16/2001 | EP0994706A4 Method and compositions for administering taxanes orally to human patients |
| 05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
| 05/16/2001 | EP0842165B1 Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| 05/16/2001 | EP0810870B1 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof |
| 05/16/2001 | CN1295616A Tumor-associated antigen derivatives from MAGE family, and nucleic acid sequence encoding them |
| 05/16/2001 | CN1295614A Modulator for function of receptor of TNF/NGF receptor family and other protein |
| 05/16/2001 | CN1295580A Method for producing mouse and haman endogenous vascular formation inhibition factor |
| 05/16/2001 | CN1295579A Therapeutic uses of keratinocyte growth factor-2 |
| 05/16/2001 | CN1295578A Pharmaceuticals for imaging of angiogenic disorders |
| 05/16/2001 | CN1295574A Porphyrins and their use as photosensitizer |
| 05/16/2001 | CN1295484A Formulations for protection of PEG-interferon alpha conjugates |
| 05/16/2001 | CN1295078A Antisense thio-oligonucleic acid of target protein kinase C-alpha and its medicine composition and application in treating cancer |
| 05/16/2001 | CN1295077A Intermediate of ganglioside GM3 analogue using fluorine to substitute sialic acid at 9-position |
| 05/16/2001 | CN1295065A Phenyl heterocyclic compound used as epoxy enzyme -2 inhibitor |
| 05/16/2001 | CN1294922A Chinese medicine capsule for treating tumor and its preparation |
| 05/16/2001 | CN1294911A Substituted nitrobenzene derivative for medicine and other use |
| 05/16/2001 | CN1065874C Novel peptides, preparation and use thereof |
| 05/16/2001 | CN1065752C Sanzhufuzheng anticancer oral liquor and preparation method thereof |
| 05/15/2001 | US6232460 Isolated nucleic acid molecule which encodes an SCP-1 mutein |
| 05/15/2001 | US6232459 Synaptojanin isoform |
| 05/15/2001 | US6232454 Nucleic acid and amino acid sequences and use in diagnosis, treatment, and prevention of cancer and immune disorders |
| 05/15/2001 | US6232452 Autosomal dominant disorder of growths in many tissues and organs identified on chromosome 16 deletion mutations; use in disease diagnosis and screening; the gene may behave as a tumor suppressor |
| 05/15/2001 | US6232449 Persephin and related growth factors |
| 05/15/2001 | US6232443 Useful markers in diagnosing and monitoring cancerous renal cells; detecting cell proliferative disorders |
| 05/15/2001 | US6232338 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors |
| 05/15/2001 | US6232327 And physiologically tolerable acid addition salts, n-oxides |
| 05/15/2001 | US6232315 Method for treating inflammatory diseases by administering a thrombin inhibitor |
| 05/15/2001 | US6232308 Useful for inhibiting bone resorption, treating and preventing osteoporosis, inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, and angiogenesis |
| 05/15/2001 | US6232307 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole compounds useful as estrogenic agents |
| 05/15/2001 | US6232305 Substituted amino bicyclic-β-lactam penam and cepham derivatives as cysteine protease inhibitors |
| 05/15/2001 | US6232299 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| 05/15/2001 | US6232295 Cell-specific contrast agent and gene delivery vehicles |
| 05/15/2001 | US6232286 Methods of stimulating mitogenesis in glial cells using glial mitogenic factors |
| 05/15/2001 | US6232077 Genetic engineering and expression; cancer diagnosis |
| 05/15/2001 | US6232071 Tenascin-C nucleic acid ligands |
| 05/15/2001 | US6232064 Fibrosis and atherosclerosis determination |
| 05/15/2001 | US6231893 Immunosuppressive and tumour-suppressive bone marrow factor |
| 05/15/2001 | US6231854 Methioninase formulations and use in diagnostic methods |
| 05/15/2001 | US6231833 Administering to the mammal for treating serotonin system related disorders an effective amount of 2,7-substituted octahydro-1h-pyrido(1,2-a)pyrazine derivative as ligands for serotonin receptor |
| 05/15/2001 | US6231536 Method and compositions for treatments of cancers |
| 05/15/2001 | CA2325667A1 Anti-malignant tumor agent used in malignant neoplasms including cancers |
| 05/15/2001 | CA2158054C Conjugates of proteins and bifunctional ligands |
| 05/15/2001 | CA2041638C Recombinant polynucleotide constructs suitable for providing secretion of pai-2 |
| 05/10/2001 | WO2001032926A2 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | WO2001032925A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | WO2001032923A1 Antisense inhibition of pi3 kinase p55 gamma expression |
| 05/10/2001 | WO2001032910A2 27 human secreted proteins |
| 05/10/2001 | WO2001032900A1 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 05/10/2001 | WO2001032891A2 Human lipase |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032885A2 Human lipase |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032851A2 Modular transport systems for molecular substances and production and use thereof |
| 05/10/2001 | WO2001032843A2 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 05/10/2001 | WO2001032837A1 19 human secreted proteins |
| 05/10/2001 | WO2001032714A1 Recombinant fusion molecules |